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Key Points 
Question: To what extent can the beneficial effect of endovascular therapy (EVT) on functional outcome 
be explained by treatment-associated reduction in follow-up infarct volume? 
Findings: In this pooled data analysis including 1665 patients with an acute ischemic stroke presenting 
within 6 hours, a mere 12% of the beneficial effect of EVT on functional outcome is explained by a 
reduction in infarct volume. 
Meaning: The infarct volume assessed on imaging post-treatment is currently not a valid proxy for 
estimating treatment effect in phase II studies. 
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ABSTRACT (344/350) 
Importance: It is assumed that the positive treatment effect of endovascular therapy (EVT) is caused by 
the salvage and preservation of brain tissue. It remains unclear to what extent a reduction in follow-up 
infarct volume (FIV) explains the improved functional outcome after EVT in acute ischemic stroke 
patients. 
Objective: To study whether FIV mediates the effect of EVT on functional outcome. 
Design: Patient data of seven randomized trials were pooled. FIV was assessed on 24-hour or 1-week 
follow-up CT or MR after stroke onset. FIVs in patients allocated to EVT were compared to patients in 
the control group. Mediation analysis was performed to examine the causal chain in which EVT 
determines FIV and where FIV (the mediator) is presumed to determine the functional outcome. 
Setting: Multicenter 
Participants: 1690 of the 1764 patients had follow-up imaging acquired between 12 hours and 2 weeks 
after stroke onset. Twenty-five patients were additionally excluded, resulting in a total of 1665 included 
patients. 
Main outcome and Measure: The primary outcome was the functional outcome as assessed on ordinal 
90-day modified Rankin Scale (mRS). 
Results: Median FIV of 1665 patients was 41mL (IQR 14-120), and median mRS was 3 (IQR 2-4). 
Patients allocated to EVT had significantly smaller FIVs compared to controls (p<0.007), with a median 
of 33mL (IQR 11-99) in the EVT group (n=821) and 51mL (IQR 18-134) in the control group (n=844). 
FIV was a strong predictor of functional outcome with an adjusted common odds ratio (acOR) of 0.46 
(95%CI: 0.39–0.54, p<0.001). FIV partially mediated the relationship between treatment type and mRS, 
as EVT still had a substantial effect on functional outcome after adjustment for FIV (acOR of 2.22 
(95%CI: 1.52–3.21, p<0.001). Merely 12% (95%CI: 1%-19%) of the beneficial effect of EVT on 
functional outcome is explained by a reduction in FIV. 
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Conclusions and Relevance: Reduction in FIV among patients with acute ischemic stroke treated with 
EVT only partially explains functional outcome, indicating that additional mechanisms underpin the 
benefits of EVT. FIV is not yet a valid proxy for estimating treatment effect in phase II studies. 
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INTRODUCTION 
Endovascular therapy (EVT) substantially reduces disability in acute ischemic stroke patients 
with a large vessel occlusion in the anterior circulation.1–7 It is assumed that this positive 
treatment effect is caused by the salvage and preservation of brain tissue. This idea is 
strengthened by many studies that have shown a strong association between the extent of 
ischemic tissue injury assessed at follow-up imaging and functional outcome.8–11 With this in 
mind, the follow-up infarct volume (FIV) has been suggested as an early measure of treatment 
efficacy since this represents a potentially more objective estimate of the pathological response 
to treatment than traditional clinical outcomes. However, the validity of a potential surrogate 
outcome measure depends upon the demonstration that the effect of therapy on that surrogate 
accurately reflects and reliably predicts the effect on the clinical endpoint.12 Formal testing 
through a causal mediation analysis is relevant to establishing the full potential of FIV as an 
early measure of treatment efficacy.  
Only one study by the Endovascular Revascularization With Solitaire Device Versus Best 
Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT) investigators5 
examined if the effect of EVT on functional outcome was mediated by FIV, and reported that 
FIV did not mediate the relation between treatment type and functional outcome in their study 
data.13 However, no estimates were reported on the proportion of EVT effect that is explained by 
FIV. In an exploratory analysis of Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) data, only a small 
proportion of the treatment effect could be explained by FIV, but estimates were not precise.14 
Hence, it still remains unclear to what extent the beneficial effect of EVT on functional outcome 
is explained by treatment-associated reduction in FIV. We investigated the mediating effect of 
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FIV on the association between treatment and functional outcome by analyzing pooled individual 
patient data from seven randomized trials of thrombectomy for acute ischemic stroke.1–7 
METHODS 
Data in this study are from the pooled individual patient data of the Highly Effective Reperfusion 
Evaluated in Multiple Endovascular Stroke Trials (HERMES) collaboration. This collaboration 
was established by trial investigators of seven recent randomized controlled trials (Endovascular 
Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on 
Minimizing CT to Recanalization Times [ESCAPE], Extending the Time for Thrombolysis in 
Emergency Neurological Deficits — Intra-Arterial [EXTEND-IA], Solitaire With the Intention 
For Thrombectomy as Primary Endovascular Treatment [SWIFT PRIME], REVASCAT, MR 
CLEAN, Pragmatic Ischemic Stroke Thrombectomy Evaluation [PISTE], and Trial and Cost 
Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke [THRACE]) 
that investigated the efficacy of EVT in patients with acute ischemic stroke due to large vessel 
occlusions. Design features and inclusion criteria have previously been described.6,7,15  
All subjects enrolled in each trial, except for MR CLEAN, had 24-hour follow-up brain imaging 
with either non-contrast computed tomography (CT) or magnetic resonance (MR) imaging. The 
THRACE trial protocol additionally required follow-up imaging at day 7 or at hospital discharge. 
Participating centers in MR CLEAN were required to perform follow-up imaging at 5-7 days. In 
EXTEND-IA, ESCAPE, SWIFT PRIME, REVASCAT and PISTE, 5-day follow-up imaging 
occurred at the discretion of the intervention site. This study included all patients that had 
available follow-up imaging, acquired at least 12 hours after symptom onset with an upper limit 
of 2 weeks (336 hours). 
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Outcome measures 
The primary outcome was the degree of disability as scored on the modified Rankin Scale (mRS) 
at 90 days, considered as an ordinal outcome.16 Assessment of secondary imaging outcome 
measures was performed on follow-up CT or MR. When multiple follow-up image data were 
available, the latest scan within the 12 hours - 2 week time window was selected for assessment. 
In case both CT and MR images were acquired, MR was the modality of choice and in that, 
diffusion-weighted imaging (DWI) was the preferred sequence due to its sensitivity in the 
detection on early infarcts. Infarcts were identified as intra-axial hypodense (CT) or hyperdense 
(MR [DWI]) regions within the affected hemisphere. Areas with parenchymal hemorrhage 
(within or adjacent to the infarct), cerebral edema extending into the contralateral hemisphere, 
and those causing ventricular and sulcal effacement were included in the lesion. Infarcts in the 
ipsilateral hemisphere with characteristics of old infarct were categorized as preexistent and were 
not included in the FIV. In case of decompressive hemicraniectomy with no available pre-
surgery scan, only the ischemic lesion within the theoretical boundaries of the skull was 
included. . In case of CT, validated software was initially used to segment infarcts and volumes 
were calculated based upon planimetry.17 Infarct volumes on MR were calculated using 
planimetry, manually outlined by an experienced observer (A.M.M.B or I.G.H.J). All infarct 
boundaries (on both modalities) were checked by an expert neuroradiologist (W.vZ, L.F.B or 
C.B.M) and adjusted where necessary. A standardized window and level setting for CT was set 
in that to limit variation between observers; window width was 30 Hounsfield units (HU) and 
center level was 35 HU. Discrepancies were resolved by a consensus reading with the two 
neuroradiologists. FIVs were calculated in milliliters (mL). Infarct location was defined by 
laterality (left or right hemisphere) and involvement of the 10 distinct anatomical regions of the 
Alberta Stroke Program Early CT score (ASPECTS) template18, assessed by one of the same 
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expert neuroradiologists (W.vZ, L.F.B or C.B.M). In case of MR, an ASPECTS region with an 
infarction encompassing more than 20% of that region was classified as an infarct positive region 
to minimize differences between MR and CT. Hemorrhagic transformations were scored 
according to the anatomical description of the Heidelberg Classification.19 All readers were 
blinded to treatment assignment, trial, and clinical findings.   
Statistical Analysis 
Dichotomous variables were presented as proportions. Continuous variables were tested for 
normality using the Shapiro-Wilk test and reported as mean ± standard deviation (SD) when 
normally distributed, or as median and interquartile range (IQR) otherwise. Differences in FIVs 
between EVT and control group were tested for significance with the Wilcoxon Rank-sum test. 
The statistical approach in this study was based on a previous post-hoc analysis by the MR 
CLEAN investigators.20 
Mediation of treatment effect by follow-up infarct volume 
To assess the contribution of infarct size reduction on the positive effect of EVT on functional 
outcome, mediation analysis was performed using Baron and Kenny’s template21 with FIV as 
mediating variable. Figure 1 illustrates the causal model where the treatment type (EVT or 
control) determines the FIV after an acute ischemic stroke and where FIV (the mediator) is the 
determinant of functional outcome at 90 days. To perform mediation analysis, it is necessary to 
test three causal pathways: 1) association of treatment with 90-day mRS, 2) association of 
treatment with FIV, and 3) association of FIV with 90-day mRS, controlling for treatment type. 
If all three associations are confirmed, mediation (indirect effect) can be established in a fourth 
step through estimation of the direct effect (c’) (see Table 1). According to Baron and Kenny, the 
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mediating effect is ‘full’ when c’ is zero, ‘partial’ when c’ is greater than zero. Mediation is 
‘absent’ when not all causal steps are satisfied. 
All pathways were tested using univariable and multivariable regression analysis. FIV was log 
transformed (log+1) to best satisfy the linear model (distribution of residuals was normal and 
homoscedasticity of the data was preserved). The effect of treatment on FIV (pathway a) was 
tested using linear regression modeling and reported as adjusted and unadjusted βs with its 95% 
confidence interval (CI). All other pathways were tested using ordinal linear regression and 
reported as adjusted and unadjusted common odds ratios (acOR and cOR, respectively) with 
associated 95% CIs. Multivariable modeling included the variables infarct location, hemorrhage 
type, and the pre-specified prognostic variables age and score on the National Institute of Health 
Stroke Scale (NIHSS) at baseline. The proportion of the effect that is mediated through FIV was 
estimated by dividing the log odds ratios (OR) of the indirect effect (ab) by the log OR of the 
total effect (c).22,23 Given the ordinal nature of the outcome measure, the method of 
VanderWeele and colleagues23 was used to compute mediation effects based on OR, with 95% 
CIs derived from bootstrap methods. Missing variables were included after imputation of the 
relevant covariate with median values of the non-missing data. For all ORs and other parameter 
estimation, mixed-effects modeling with a random effect for trial were performed to account for 
between-trial variance.  
Sensitivity analyses 
Infarcts may still evolve within the first week after onset due to ongoing hypoperfusion or 
because vasogenic edema increases the lesion volume.24,25 Accordingly, FIV assessment is 
dependent on the timing of image acquisition. A sensitivity analysis was conducted in subjects 
with FIVs assessed on imaging acquired after 48 hours of symptom onset. In addition, MR may 
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provide more accurate estimates of FIV than CT, since tissue contrast on MR is superior to CT. 
A second sensitivity analysis was performed with MR imaging only.  
All statistical analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC, USA) and 
R version 3.2 (R Foundation for Statistical Computing, Vienna, Austria). P-values were two-
sided and p<0.05 indicated statistical significance in all analyses.  
Role of the funding source 
The funder of the study had no role in study design, data collection, analysis, or interpretation, 
writing of this article, or the decision to submit this study for publication. The corresponding 
author had full access to all the data in the study and had final responsibility for the decision to 
submit for publication. 
RESULTS 
In HERMES, 1690 (95.8%) out of 1764 patients had follow-up imaging acquired between 12 
hours and 2 weeks after stroke symptom onset with a median of 30 hours (IQR 24-137). Twenty-
five patients were additionally excluded because of poor image quality or difficulties precluding 
accurate infarct determination, resulting in a total of 1665 patients for this analysis. 
Baseline characteristics of both treatment groups are shown in Table 2. Eight-hundred-twenty-
one subjects were allocated to the EVT arm and 844 to the control arm. Overall, median FIV was 
41 mL (IQR: 14-120 mL) and 39% (651/1650) achieved functional independence (mRS 0-2) at 3 
months. Patients allocated to EVT had significantly smaller FIVs compared to controls, with a 
median of 33 mL (IQR 11-99) in the EVT group and 51 mL (IQR 18-134) in the control group 
(p<0.007) (Table 3). Successful reperfusion (TICI 2b-3) was achieved in 76% (523/690) of the 
patients in the intervention arm with evaluable angiographic imaging. In the intervention group, 
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median FIV in the substantial reperfused patients was 28 mL versus 86 mL for those who were 
not (TICI 0-2a) (p<0.001). 
Mediation analysis 
EVT was independently associated with a better functional outcome (Step 1; acOR = 2.28 
[95%CI: 1.55 – 3.36, p<0.001]), and with smaller FIV (log transformed) (Step 2; β = -0.13 
[95%CI: -0.19 to -0.07, p<0.001], see Table 4). In adjusted analysis, FIV (log transformed) was a 
strong predictor of functional outcome (Step 3) with an acOR of 0.46 (95%CI: 0.39 – 0.54, 
p<0.001); EVT similarly predicted good function outcome (Step 4; OR of 2.22 (95%CI: 1.52 – 
3.21, p<0.001) (Table 4 and Supplemental Table 1). Other independent predictors of functional 
outcome included age (acOR 0.62; p<.001), baseline NIHSS (acOR 0.82 per 5 points; p=.001), 
hemorrhagic infarct type 2 (acOR 0.73; p=.043), intraventricular hemorrhage (acOR 0.29; 
p=0.002), and involvement of the ASPECTS Internal Capsula (acOR 0.45; p<0.001) and M5 
(acOR 0.77; p=0.042) regions.   
In the mediation analysis steps one through three were satisfied. Step four established partial 
mediation of FIV on the association between treatment and 90-day mRS; after adjustment for the 
mediator FIV, EVT still had a substantial effect on functional outcome. For the adjusted model, 
12% (95%CI: 1%-19%) of EVT effect on functional outcome was explained by the mediator 
FIV. This proportion was 18% (95%CI: 3%-34%) for the unadjusted model.  
Figure 2 depicts the relation between FIV and estimated probability of functional independence 
for all patients, stratified by treatment type and adjusted for baseline characteristics. This 
illustrates that the difference in estimated probability between treatments was mainly present in 
patients with smaller FIVs, where the absolute benefit of EVT appears highest. Supplemental 
Figures 1 and 2 show this relation for subjects who achieved successful reperfusion (TICI score 
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2b to 3 in the EVT group), and who did not achieve any reperfusion (TICI score 0). These 
illustrate an average increased likelihood of good outcome when reperfusion therapy was 
successful, but lack statistical precision due to the dominant proportion of patients with 
successful reperfusion.  
Sensitivity analyses 
Results of the tested pathways in our sensitivity analyses are shown in Supplemental Table 2. 
The first sensitivity analysis, which only included follow-up imaging past 48 hours of symptom 
onset (n=688), showed no substantial differences from the main analysis. The proportions of 
explained mediated effect by FIV were 7% (95%CI: -5% to 22%) and 23% (95%CI: -2% to 
55%) for the adjusted and unadjusted analysis, respectively. The second sensitivity analysis with 
MR imaging (n=279) showed proportions of 0% (95%CI: -25% to 24%, adjusted) and 10% 
(95%CI: -38% to 56%, unadjusted) for the explained mediated effect. However, treatment was 
not significantly associated with FIV (pathway a), meaning that mediation was absent in this 
analysis.  
DISCUSSION 
Our analysis of the pooled recent EVT trial data showed that FIV at subacute time points only 
partially mediates treatment effect on functional outcome at three months, despite being a strong 
outcome predictor. Merely one-eighth of the variance in functional outcome as captured by the 
mRS could be attributed to a difference in FIV, suggesting that there are multiple component 
causes of clinical outcome at 90 days. 
Several studies have previously addressed the relation between FIV and functional outcome after 
an acute occlusion of the proximal anterior circulation.9–11 In concordance with our results, all 
demonstrated that FIV is a strong predictor of functional outcome and found that subjects treated 
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with EVT had significantly smaller FIVs compared to controls. One possibility is that there were 
imprecise FIV measurements and varying infarct sizes due to differences in follow-up 
acquisition time. However, the fact that patients were randomized and that our sensitivity 
analysis in patients with late follow-up imaging did not alter our results stresses that these factors 
cannot clarify the small proportion of explained effect.  
Mechanisms other than FIV are at play that affects this causal pathway, such as the eloquence of 
certain brain areas. A previous study demonstrated large differences between brain regions in 
functional outcome when affected by a stroke, even when corrected for infarct volume.26 Patients 
with small infarcts in eloquent regions are likely to have poor outcome despite a small total 
infarct volume. We used laterality and involvement of follow-up ASPECTS regions as a measure 
of infarct location in our analysis, and found that involvement of the internal capsule and M5 
region was inversely associated with functional outcome. Considering the fact that these areas 
are linked to the motor cortex and corticospinal tract underlines the importance of brain 
eloquence. This association is additionally likely because the modified Rankin Scale is heavily 
weighted towards motor functions, particularly walking.  Unfortunately, we do not have more 
detailed measurement of infarct location to better discriminate the total effect of brain eloquence.  
Interestingly, we found that patients in the EVT arm had significantly better functional outcome 
than controls, even after controlling for FIV. This finding remained consistent in our sensitivity 
analyses with comparable effect sizes. The difference between treatment arms was mainly driven 
by subjects with smaller infarcts, where the impact of treatment was more pronounced. This 
effect was even stronger in patients who had successful reperfusion. Several hypotheses could 
possibly explain this phenomenon. First, studies have reported significant infarct growth between 
24 hours and 1 week follow-up imaging24 (whether or not driven by edema), but little is known 
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about the course of infarction after the follow-up imaging period of 1 week. It could be that 
patients randomized to the control arm continue to have hypoperfusion and consequently, true 
infarct growth even a week after ictus. Second, the binary definition of infarcted versus non-
infarcted may be an over-simplification. There may be variation in the severity of injury within 
tissue defined as infarcted and potentially this may be less marked in EVT patients. Moreover, 
tissue outside the defined infarct may have undetected injury (e.g. selective neuronal loss) and 
this may be less severe in EVT patients.27 Future studies are encouraged to use more 
sophisticated imaging approaches to increase insight in the pathophysiological process. Follow-
up imaging near the 90-day mRS evaluation time point or magnetization transfer ratio imaging to 
assess axonal damage might help addressing this issue. Third, one could speculate about the 
possibility that the apparent benefits of EVT outside of FIV restriction are not from treatment 
alone, but that these may also result from differences in after care. Unfortunately, evidence is 
scarce to support these theories. 28  
Our study has limitations. First, because FIV measurements might be less accurate on CT and 
because treatment may have other pathophysiological effect that one cannot see on CT, we 
performed a sensitivity analysis with MR imaging only. In this analysis, effect sizes did not 
differ significantly from the main analysis. However, mediation could not be established due to 
absence of an association between treatment and FIV. This can possibly be explained by the 
small number of patients in this sub-analysis. In addition, MR is also not immune to FIV 
measurement error. However, it is noteworthy that a previous study investigating the association 
between FIV and functional outcome showed similar strengths of correlations for both MR and 
CT with mRS, as well as early and late imaging. [ref JNIS] Second, the fact that the last scan of 
each patient was selected for FIV assessment could have led to a bias, as patients with 
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complications and deterioration would have had more late imaging. Third, to obtain trustworthy 
results from mediation analysis, unmeasured confounding must not exist between parameters in 
the examined causal model. This is a strong assumption, especially when we consider that the 
independent contributions of the many interconnected biological processes to the final clinical 
outcome are not fully understood and are likely to vary among individuals. However, we can 
expect that this unmeasured confounding effect is minimal as patients across all trials were 
randomized and all observers were blinded to information outside of relevant imaging material. 
Fourth, the proportions of explained mediated effect could never reach the theoretical value of 
0%. This is because our model would no longer suffice in such a situation, as the mediator FIV 
would not remain significant. The same applies for the hypothetical value of 100%, as all 
variables (even when that biological pathway is completely non-existent) exert some form of 
influence, albeit being noise. Further work needs to be done to understand the mediation pathway 
and the limitations of mediation analysis. 
In conclusion, our results show that while FIV is a strong predictor of functional outcome, 
successful treatment with EVT resulting in smaller FIV is only for a modest one-eighth 
explained by a reduction in infarct volume. FIV as it is currently measured is not yet a valid 
proxy for estimating treatment effect in phase II studies of acute ischemic stroke. 
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TABLES 
 
Table 1. Four-step approach for testing mediation  
Step Analysis Visual representation 
Step 1 
Regression analysis with X predicting Y to test for path c, Y =
B0 + B1X + e  
Step 2 
Regression analysis with X predicting M to test for path a, M =
B0 + B1X + e  
Step 3 
Regression analysis with M predicting Y to test the significance of 
path b, Y = B0 + B1M+ e                 
Step 4 
Multiple regression analysis with X and M predicting Y, Y =
B0 + B1X + B2M+ e 
 
 
  
25 
 
  
Table 2 - Baseline characteristics 
 
Characteristic EVT (n=821) Control (n=844) p-value 
Age (years), median [IQR] 68 [57-76] 68 [58-76] 0.79 
Female sex, % (n/N) 47.3% (388/821) 46.6% (393/844) 0.81 
Left hemisphere infarct, % (n/N) 47.1% (381/809) 48.7% (409/840) 0.52 
Onset to follow-up imaging acquisition in 
hours, median [IQR] 
29 [24-138] 31 [24-141] 0.61 
Modality, % (n/N)   0.36 
   CT 82.2% (675/821) 83.9% (708/844)  
   MR 17.8% (146/821) 16.1% (136/844)  
NIHSS at baseline, median [IQR] 17 [14-20] 17 [13-21] 0.93 
Alteplase (tPA) delivered, % (n/N) 88.2% (724/821) 91.5% (772/844) 0.028 
Diabetes mellitus, % (n/N) 14.5% (119/819) 17.9% (151/842) 0.063 
Hypertension, % (n/N) 53.6% (439/819) 59.0% (497/843) 0.030 
Tobacco use, % (n/N) 37.7% (280/742) 36.8% (286/777) 0.71 
Onset to alteplase (tPA) (min), median [IQR] 115 [85-155] 119 [85-161] 0.075 
Onset to randomization (min), median [IQR] 181 [141-240] 184 [140-248] 0.80 
Onset to reperfusion (min), median [IQR] 291 [230-355] NA NA 
ASPECTS at baseline, median [IQR] 8 [7-9] 8 [7-9] 0.20 
Occlusion location, % (n/N)   0.91 
   Not available 5.7% (47/821) 5.5% (46/844)  
   ICA 24.5% (201/821) 26.2% (221/844)  
   M1 61.8% (507/821) 61.3% (517/844)  
   M2 7.9% (65/821) 7.0% (59/844)  
   Other 0.1% (1/821) 0.1% (1/844)  
Collateral score, % (n/N)   0.75 
   0 1.0% (6/606) 1.1% (7/627)  
   1 14.9% (90/606) 17.1% (107/627)  
   2 43.7% (265/606) 42.3% (265/627)  
   3 40.4% (245/606) 39.6% (248/627)  
NIHSS, National Institutes of Health and Stroke Scale score; ASPECTS, Alberta Stroke Program Early 
CT; ICA, internal carotid artery 
26 
 
Table 3. Outcomes per treatment allocation group 
Characteristic EVT (n=821) Control  (n=844) p-value 
Follow-up infarct volume (mL), median [IQR] 33 [11-99] 51 [18-134] 0.007 
mRS at 90 days, median [IQR] 3 [1-4] 4 [2-5] <0.001 
Hemorrhage a, % (n/N) 
   Hemorrhagic infarct type 1 (HI-1) 14.1% (116/821) 13.4% (113/844) 0.67 
   Hemorrhagic infarct type 2 (HI-2) 12.3% (101/821) 11.1% (94/844) 0.49 
   Parenchymal hematoma type 1 (PH-1) 8.5% (70/821) 6.5% (55/844) 0.14 
   Parenchymal hematoma type 2 (PH-2) 8.3% (68/821) 5.9% (50/844) 0.069 
   Remote parenchymal hematoma (rPH) 1.6% (13/821) 0.9% (8/844) 0.28 
   Intraventricular hemorrhage (IVH) 2.4% (20/821) 2.7% (23/844) 0.76 
   Subarachnoid hemorrhage (SAH) 2.8% (23/821) 1.7% (14/844) 0.14 
   Subdural hemorrhage (SDH) 0.0% (0/821) 0.4% (3/844) 0.25 
Reperfusion, % (n/N) 
   TICI 2b-3 75.7% (518/684)  NA 
EVT = endovascular therapy; TICI = thrombolysis in cerebral ischemia;  
a Hemorrhages scored according to the anatomical description of the Heidelberg Classification 
TICI 2b-3 indicates successful reperfusion 
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Table 4. Mediating effect of follow-up infarct volume on the association between treatment and ordinal 90-day 
modified Rankin Scale, FIV transformed by ln(FIV+1) 
Pathway 
Unadjusted Adjusted 
Effect 
measure 
Value 95% CI p-value Effect measure Value 95% CI p-value 
a β -0.28 -0.41 -- -0.14 <0.001 β -0.13 -0.19 -- -0.07 <0.001 
b cOR 0.45 0.42 – 0.48 <0.001 acOR 0.46 0.39 – 0.54 <0.001 
c cOR 2.17 1.38 – 3.41 <0.001 acOR 2.28 1.55 - 3.36 <0.001 
c’ cOR 1.87 1.25 – 2.81 0.002 acOR 2.08 1.44 – 3.00 <0.001 
Path a represents the regression coefficient of the association between treatment (control or endovascular therapy) and 
FIV;  
b between FIV and 90-day mRS; c between treatment and 90-day mRS; and c’ between treatment and 90-day mRS, 
controlling for FIV. Multivariable regression analysis included FIV, location, hemorrhage type, age, and National 
Institutes of Health and Stroke Scale score. 
FIV = follow-up infarct volume; mRS = modified Rankin Scale; cOR = common odds ratio; CI = confidence interval 
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FIGURE LEGENDS 
 
Figure 1: A pictorial representation of the causal pathway in acute ischemic stroke patients. Total 
effect (c) = direct effect (c’) + indirect effect (ab).  
 
 
 
Figure 2: Relation between FIV and estimated probability of functional independence (point 
estimates ± 95% CI), stratified by treatment and adjusted for baseline characteristics  
 
 
 
